EyeDNA Therapeutics Receives Rare Pediatric Disease Designation from FDA for its Investigational Gene Therapy HORA-PDE6b for Patients with Retinal Dystrophy due to PDE6b Gene Mutations
17 déc. 2024 06h00 HE
|
Coave Therapeutics
PDE6b-related Retinitis Pigmentosa is a rare inherited retinal dystrophy affecting up to 3,000 people in the US Symptoms often start in childhood leading to blindness by midlife with no approved...
Alkeus Pharmaceuticals Announces Positive Interim Results Demonstrating No Signs of Disease Progression in Early-Stage Stargardt Disease Patients Treated with Gildeuretinol
08 mai 2024 09h00 HE
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals announces interim data demonstrating no signs of disease progression in early-stage Stargardt patients treated with gildeuretinol.
EyeDNA Therapeutics Announces Positive 24-month Data Presented at ARVO from Ongoing Phase I/II Trial of HORA-PDE6b Gene Therapy in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b
07 mai 2024 03h00 HE
|
Coave Therapeutics
Clinically meaningful benefit in visual functions and good safety profile of HORA-PDE6b is confirmed at 24-month follow-up Phase I/II results will be discussed with US and...
Alkeus Pharmaceuticals Announces Presentation of Positive Gildeuretinol Data in Early-Stage Stargardt Patients During the ARVO 2024 Annual Meeting May 5-9
01 mai 2024 09h00 HE
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals Announces Presentation of Positive Gildeuretinol Data in Early-Stage Stargardt Patients During the ARVO 2024 Annual Meeting May 5-9
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
30 avr. 2024 07h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
eyeDNA Therapeutics to Present 2-year Follow-up Phase I/II Data on its Investigational Gene Therapy HORA-PDE6b for Retinitis Pigmentosa at the ARVO 2024 Annual Meeting
25 avr. 2024 06h00 HE
|
Coave Therapeutics
Paris, France, April 25, 2024 – eyeDNA Therapeutics (‘eyeDNA’), a newly created subsidiary of Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies,...
Doheny Eye Institute Announces Upcoming Presentations at ARVO 2024 Annual Meeting
24 avr. 2024 09h00 HE
|
Doheny Eye Institute
PASADENA, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Doheny Eye Institute, one of the nation’s leading vision research institutions, announced that more than 25 of its scientists and...
Coave Therapeutics to Present at Upcoming Conferences
27 mars 2024 07h00 HE
|
Coave Therapeutics
Paris, France, March 27, 2024 – Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies, announces that its management will be attending the following...
Dr. SriniVas R. Sadda Named 2023-2024 ARVO President Elect
27 juin 2023 09h00 HE
|
Doheny Eye Institute
PASADENA, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- Doheny Eye Institute, one of the nation’s leading vision research institutions, announced that SriniVas R. Sadda, MD, was named President Elect of...
Clearside Biomedical Presents Compelling Data at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting
27 avr. 2023 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., April 27, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through...